Form 4: Coherus BioSciences Director Acquires Stock Options

Mats Wahlstrom, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.

Summary

• On June 3, 2024, Mats Wahlstrom, a director of Coherus BioSciences, Inc., acquired stock options for 112,000 shares.
• The exercise price of these options is $1.76.
• The options vest 100% on June 3, 2025, contingent upon Wahlstrom's continued service with the company.
• The options expire on June 3, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director could be interpreted as a mildly positive signal, suggesting confidence in the company's prospects, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

This is a standard SEC Form 4 filing, reflecting a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates